Calyxt Announces Full Exercise of Over-Allotment Option and Closing of its Initial Public Offering
July 25 2017 - 4:01PM
Business Wire
Cellectis S.A. (NASDAQ:CLLS) and Calyxt, Inc. (NASDAQ:CLXT)
announced today the closing of Calyxt’s initial public offering of
8,050,000 shares of its common stock at the initial public offering
price of $8.00 per share (the “Offering”). The number of shares
issued in the Offering includes the exercise in full of the
underwriters’ option to purchase up to 1,050,000 additional shares.
Calyxt received approximately $64.4 million in proceeds from the
offering, before deducting underwriting fees and estimated offering
expenses. Calyxt’s shares of common stock are traded on the NASDAQ
Global Market under the symbol “CLXT”.
Calyxt is Cellectis’ gene editing agriculture company. Cellectis
owns approximately 79.9% of Calyxt’s outstanding shares of common
stock.
Citigroup, Jefferies and Wells Fargo Securities acted as joint
book-running managers for the proposed offering. BMO Capital
Markets and Ladenburg Thalmann acted as co-managers.
A registration statement on Form S-1 relating to these
securities was declared effective by the U.S. Securities and
Exchange Commission. A copy of the final prospectus relating to
this Offering may be obtained from Citigroup Global Markets Inc.,
c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717, or by telephone at (800) 831-9146, Jefferies
LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison
Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877)
547-6340, or by e-mail at Prospectus_Department@Jefferies.com, or
Wells Fargo Securities, Attention: Equity Syndicate Department, 375
Park Avenue, New York, New York, 10152, at (800) 326-5897 or by
email at cmclientsupport@wellsfargo.com.
The final prospectus is also available at www.sec.gov. This
press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
This press release contains inside information within the
meaning of Article 7(1) of the EU Market Abuse Regulation.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170725006440/en/
Media:Jennifer Moore, 917-580-1088VP
Communicationsmedia@calyxt.com / media@cellectis.comorKCSA
Strategic CommunicationsCaitlin Kasunich,
212-896-1241ckasunich@kcsa.comorNick Opich,
212-896-1206nopich@kcsa.comorInvestor Relations:Simon
Harnest, 646-385-9008VP Corporate Strategy and
Financesimon.harnest@cellectis.com
Calyxt (NASDAQ:CLXT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Calyxt (NASDAQ:CLXT)
Historical Stock Chart
From Sep 2023 to Sep 2024